ストックスクリーナーアプリを入手
25.98
7.94%
1.91
アフターアワーズ：
26.00
0.02
+0.08%
前日終値:
$24.07
開ける：
$24.15
24時間の取引高:
774.24K
Relative Volume:
2.19
時価総額：
$1.44B
収益：
$29.71M
当期純損益:
$-69.15M
株価収益率:
-23.09
EPS:
-1.1251
ネットキャッシュフロー:
$-52.28M
1週間 パフォーマンス:
+5.10%
1か月 パフォーマンス:
+8.75%
6か月 パフォーマンス:
+29.90%
1年 パフォーマンス:
+69,739%
1日の値動き範囲:
$22.95
$26.31
1週間の範囲:
$22.95
$26.31
52週間の値動き範囲:
$14.72
$34.19
Aktis Oncology Inc Stock (AKTS) Company Profile
Compare AKTS vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
25.98 | 1.33B | 29.71M | -69.15M | -52.28M | -1.1251 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-09 | 開始されました | H.C. Wainwright | Buy |
| 2026-02-03 | 開始されました | BofA Securities | Buy |
| 2026-02-03 | 開始されました | JP Morgan | Overweight |
| 2026-02-03 | 開始されました | Leerink Partners | Outperform |
| 2026-02-03 | 開始されました | TD Cowen | Buy |
| 2024-01-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-09-06 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-01-24 | 開始されました | B. Riley Securities | Buy |
| 2021-02-02 | 繰り返されました | Craig Hallum | Buy |
| 2021-01-15 | 繰り返されました | Craig Hallum | Buy |
| 2019-09-18 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2019-07-10 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2019-05-13 | 繰り返されました | Craig Hallum | Buy |
| 2019-02-05 | 繰り返されました | Craig Hallum | Buy |
| 2019-02-05 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2018-12-18 | 開始されました | Craig Hallum | Buy |
| 2018-11-30 | 開始されました | Lake Street | Buy |
| 2018-06-22 | 開始されました | Loop Capital | Buy |
| 2018-02-09 | 開始されました | Drexel Hamilton | Buy |
すべてを表示
Aktis Oncology Inc (AKTS) 最新ニュース
Blue Owl Capital Holdings LP Sells 91,129 Shares of Aktis Oncology $AKTS - MarketBeat
AKTIS ONCOLOGY INC : WEDBUSH INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $35 - Bitget
Wedbush initiates Aktis Oncology stock with outperform rating By Investing.com - Investing.com South Africa
Aktis Oncology (NASDAQ:AKTS) Earns Outperform Rating from Analysts at Wedbush - MarketBeat
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play - Yahoo Finance
Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target - marketscreener.com
BMO initiates Aktis Oncology stock with outperform rating By Investing.com - Investing.com Canada
AKTS Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Aktis Oncology (AKTS) Slips to $24.72 as Shares Trade Within Established RangeSynthetic Long - vinanet.vn
AKTS Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing Oncology Pipeline InvestmentLow Growth Earnings - vinanet.vn
Aktis Oncology, Inc.: Target Price Consensus and Analysts Recommendations | AKTS | US01021M1045 - marketscreener.com
BofA Securities Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $34 - Moomoo
AKTS SWOT Analysis: Financial Resilience Amidst Clinical Development Challenges Revealed in 10-Q Filing - GuruFocus
Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets Expectations - marketbeat.com
Aktis Oncology Q2 EPS misses estimate, sales beat consensus - scanx.trade
Aktis: Q2 Earnings Snapshot - WKYC
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 - The Manila Times
Aktis Oncology (AKTS) builds cash to $517M as losses rise with clinical spend - Stock Titan
Aktis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Aktis Oncology (AKTS) posts Q2 2026 results with $517M cash runway into 2029 - Stock Titan
Aktis Oncology (AKTS) Gains 2.94% as Shares Approach Key Resistance at $25.34Pairs Trade - vinanet.vn
Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aktis Oncology (AKTS) Slips 1.5% as Shares Hover Above Key Support at $20.64Stop Run - Vinanet
AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share Highlights Pre-Revenue ChallengesAnalyst Drop Coverage - vinanet.vn
AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share, Yet Shares Climb 2.72%Revenue Warning Signal - vinanet.vn
Insider Selling: Aktis Oncology (NASDAQ:AKTS) Director Sells 4,856 Shares of Stock - MarketBeat
AKTS|Akoustis Technologies Ord Shs|Price:24.170|Chg%:+0.280 - TradingKey
Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value? - simplywall.st
AKTIS ONCOLOGY INC : LEERINK PARTNERS ASSUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $33 - Bitget
Aktis Oncology Inc : Leerink Partners Assumes - Moomoo
Aktis Oncology director Ken Herrmann sells $119,274 in stock By Investing.com - Investing.com Australia
Aktis Oncology (NASDAQ:AKTS) Stock Passes Above 50 Day Moving AverageHere's Why - MarketBeat
Form 4 Aktis Oncology Inc For: 21 July By Investing.com - Investing.com Nigeria
Aktis Oncology (AKTS) director sells 4,856 shares after exercising options - Stock Titan
Aktis Oncology director Ken Herrmann sells $119,274 in stock - Investing.com
Aktis Oncology director Ken Herrmann disposes of common shares worth $119,256.78 - Bitget
Aktis Oncology director Ken Herrmann disposes of 3,065 common shares worth $77,279.54 - Bitget
AKTS Pulls Back After Recent Gains: Key Levels to Watch for Aktis Oncology (AKTS)Volatility Skew - dars.gov.et
Aktis Oncology, Inc. (AKTS) director sells 3,065 post-exercise - Stock Titan
Akoustis Technologies (AKTS) insider plans 4,856-share stock sale after option exercise - Stock Titan
AKTS Options Chain — NASDAQ:AKTS - TradingView
Enterprise value to EBIT forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Enterprise value to revenue forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Form 144 AKTIS ONCOLOGY For: 17 July By Investing.com - Investing.com Nigeria
Aktis Oncology, Inc. SEC Filing (Jul 17, 2026) - Stock Titan
AKTS Options Volatility — NASDAQ:AKTS - TradingView
Price to sales forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
New Options Listings Include Aktis Oncology Inc (AKTS) - GuruFocus
J.P. Morgan Keeps Their Buy Rating on Aktis Oncology, Inc. (AKTS) - The Globe and Mail
AKTS Maintained by JP Morgan -- Price Target Raised to $33.00 - GuruFocus
Aktis Oncology Inc (AKTS) 財務データ
収益
当期純利益
現金流量
EPS
Aktis Oncology Inc (AKTS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Herrmann Ken | Director |
Jul 20 '26 |
Sale |
24.56 |
4,856 |
119,274 |
0 |
| Herrmann Ken | Director |
Jul 17 '26 |
Option Exercise |
0.08 |
3,065 |
245 |
3,065 |
| Herrmann Ken | Director |
Jul 17 '26 |
Sale |
25.21 |
3,065 |
77,259 |
0 |
0.00%
3.22%
大文字化:
|
ボリューム (24 時間):